News

Synapse Biomedical Inc., a company that commercializes the NeuRx Diaphragm Pacing System (DPS), has recently announced it will be presenting data on the company’s Post Approval Study (PAS), a multi-center trial that demonstrated DPS’s safety and survival benefit, during the 26th International Symposium on ALS/MND. Data will be presented by Dr. Robert Miller, Principal Investigator of the…

Two new studies, one entitled “GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport” and another “The C9orf72 repeat expansion disrupts nucleocytoplasmic transport”, report the discovery of a key mechanism underlying amyotrophic lateral sclerosis’ onset which is associated with C9orf72 mutation (the most common genetic defect…

Last year the Ice Bucket Challenge made headlines across America when the Barrow Neurological Institute raised more than $500,000 through the international fundraising and advocacy initiative. Now, the organization is reporting that the funds accumulated will be used to support a new and potentially groundbreaking amyotrophic lateral sclerosis (ALS) study to determine why…

Diet has a significant influence on a person’s health status because it determines which nutrients are available for the body to function properly. Depending on the balance between diet and energy, body mass index (BMI) is also significantly influential to an individual’s health. Since the effects of diet on developing…

Portage Biotech, Inc. together with privately-held Biohaven Pharmaceutical Holding Company Ltd. has just acquired global intellectual property rights to an extensive 300-product portfolio by ALS Biopharma, LLC. These prodrugs included in the line up, most of which are classified as New Molecular Entities (NMEs), were originally designed and prepared by…

A new research collaboration was recently formed between Biogen Idec, the ALS Association and Columbia University Medical Center (CUMC) to study the differences and similarities in ALS’ disease progress and how an patient’s genes can influence its clinical manifestations. The joint research initiative, titled, “Genomic Translation for ALS Clinical care” (GTAC), will entail…

Presymptomatic patients suffering with amyotrophic lateral sclerosis (ALS) ingest more calories per day but have lower body-mass index (BMI) in comparison to those without ALS. These are the results of a study from researchers in the Netherlands, published by the JAMA Neurology journal, which also assessed ALS disease risk and its connections…

In a recent study entitled “ALS-Linked P56S-VAPB Mutation Impairs the Formation of Multinuclear Myotube in C2C12 Cells” researchers investigated the role of a mutation associated with ALS type-8 (ALS8)  – P56S-VAPB mutation – on skeletal muscle cells homeostasis and muscle formation. The study was published in the…

A research team at Colombia University led by Lars Brichta and Paul Greengard identified two proteins responsible for neuronal cell loss in Parkinson’s disease (PD). The study entitled “Identification of neurodegenerative factors using translatome–regulatory network analysis” appeared on 27 July, 2015 in the journal…

The ALS Therapy Development Institute has just signed a research partnership with Chaperone Therapeutics, Inc., a company that specializes in treatments that address protein misfolding and neuronal cell loss, the underlying causes of neurodegenerative disease. The new partners will be working on potential treatments for amyotrophic lateral sclerosis (ALS), in order to facilitate preclinical development…